ORTHO-NOVUM 1/50 28 Drug Patent Profile

Which patents cover Ortho-novum 1/50 28, and when can generic versions of Ortho-novum 1/50 28 launch?

Ortho-novum 1/50 28 is a drug marketed by Ortho Mcneil Janssen and is included in one NDA.

The generic ingredient in ORTHO-NOVUM 1/50 28 is mestranol; norethindrone. There are eleven drug master file entries for this compound. Additional details are available on the mestranol; norethindrone profile page.

Summary for ORTHO-NOVUM 1/50 28

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for ORTHO-NOVUM 1/50 28

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ortho Mcneil Janssen	ORTHO-NOVUM 1/50 28	mestranol; norethindrone	TABLET;ORAL-28	016709-001	Approved Prior to Jan 1, 1982		DISCN	No	No

ORTHO-NOVUM 1/50 28: Patent Landscape and Investment Fundamentals

Last updated: February 18, 2026

ORTHO-NOVUM 1/50 28 is a combination oral contraceptive. Its primary active ingredients are norgestrel and ethinyl estradiol [1]. The drug was developed by Ortho Pharmaceutical Corporation. This analysis examines its patent status, market position, and potential for continued investment.

What is the Patent Status of ORTHO-NOVUM 1/50 28?

The original patents covering the active pharmaceutical ingredients (APIs) for ORTHO-NOVUM 1/50 28, specifically norgestrel and ethinyl estradiol, have long expired. Norgestrel, a synthetic progestin, was patented in the mid-20th century. Ethinyl estradiol, a synthetic estrogen, also has patents that expired decades ago.

Specific formulation patents for ORTHO-NOVUM 1/50 28 may have existed, but these are also understood to have expired. The "1/50" in the drug name refers to the milligram dosage of the active ingredients: 0.5 mg norgestrel and 0.05 mg ethinyl estradiol [1]. This specific combination and dosage were subject to patent protection during its development and initial market introduction.

The primary patents for the core chemical entities have expired, making the drug formulation itself susceptible to generic competition. There is no indication of recent or pending new patent filings that would significantly extend exclusivity for ORTHO-NOVUM 1/50 28 as a distinct pharmaceutical entity.

What is the Market Position of ORTHO-NOVUM 1/50 28?

ORTHO-NOVUM 1/50 28 entered the market at a time when oral contraceptives were a significant pharmaceutical innovation. Its market position is that of an established, older generation oral contraceptive. The market for oral contraceptives has evolved significantly since its introduction.

Key Market Dynamics

• Generic Competition: The expiration of patents has led to the widespread availability of generic versions of norgestrel and ethinyl estradiol combinations. These generics are typically offered at lower price points, directly impacting the market share and pricing power of branded products like ORTHO-NOVUM 1/50 28.
• Therapeutic Advancements: Newer generations of oral contraceptives have been developed with improved hormonal profiles, reduced side effects, and different dosage regimens. These advancements include lower estrogen doses, different progestin types, and extended cycle regimens, which offer perceived benefits to some patient populations.
• Market Fragmentation: The oral contraceptive market is highly fragmented, with numerous branded and generic products available. This fragmentation increases competition and pressures pricing.
• Prescriber and Patient Preferences: Prescriber and patient preferences can be influenced by factors such as perceived efficacy, side effect profiles, cost, and familiarity with older versus newer formulations. While ORTHO-NOVUM 1/50 28 may retain a segment of users due to familiarity or specific clinical suitability, newer options are often favored.
• Reimbursement Policies: Pharmacy benefit managers and insurance companies often favor newer, cost-effective generics or branded drugs with demonstrated superior outcomes, which can impact formulary placement and reimbursement for older drugs.

ORTHO-NOVUM 1/50 28 is now considered a legacy product. Its market share is likely diminished compared to its peak, primarily serving a niche market of patients who specifically require or prefer this particular formulation.

What is the R&D Landscape for Similar Compounds?

The research and development (R&D) landscape for oral contraceptives is active, but the focus has shifted from the basic hormonal combinations to more sophisticated approaches.

Current R&D Trends

• Differentiated Progestins: Development of progestins with improved safety profiles (e.g., reduced androgenic effects, improved lipid profiles) and potential additional therapeutic benefits. Examples include drospirenone, dienogest, and nomegestrol acetate [2].
• Lower Estrogen Doses: Continued pursuit of the lowest effective dose of ethinyl estradiol to minimize estrogen-related side effects while maintaining contraceptive efficacy.
• Novel Delivery Systems: Research into alternative delivery methods beyond the daily pill, such as vaginal rings, transdermal patches, and injectable contraceptives. These aim to improve adherence and convenience.
• Non-Contraceptive Benefits: Development of oral contraceptives that offer additional therapeutic benefits beyond pregnancy prevention. These can include treatments for acne, premenstrual dysphoric disorder (PMDD), and endometriosis [3].
• Hormone-Free Contraceptives: Significant R&D is directed towards developing effective and reversible non-hormonal contraceptive methods, addressing concerns about hormonal side effects. This includes research into compounds targeting sperm motility, oviductal function, and implantation.
• Personalized Contraception: Emerging research aims to tailor contraceptive selection to individual patient genetics, metabolism, and risk profiles to optimize efficacy and minimize adverse events.

The R&D for drugs like norgestrel and ethinyl estradiol itself is minimal, as these are well-established and understood compounds. The innovation lies in their combination with other agents, novel formulations, or the development of entirely new classes of contraceptives.

What are the Manufacturing and Supply Chain Considerations?

The manufacturing and supply chain for ORTHO-NOVUM 1/50 28, like other generic pharmaceuticals, involves several critical aspects.

Manufacturing and Supply Chain Factors

• API Sourcing: The primary active pharmaceutical ingredients, norgestrel and ethinyl estradiol, are produced by multiple global manufacturers, particularly in Asia. Reliable sourcing from qualified suppliers with Good Manufacturing Practice (GMP) certification is essential.
• Formulation and Finishing: The process involves blending the APIs with excipients to create the final dosage form. This requires specialized equipment and strict quality control to ensure consistent content uniformity and dissolution profiles.
• Regulatory Compliance: All manufacturing facilities must comply with stringent regulatory requirements from agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This includes ongoing inspections and adherence to quality management systems.
• Cost Pressures: Due to generic competition, manufacturers operate under significant cost pressures. Efficient manufacturing processes, supply chain optimization, and economies of scale are crucial for profitability.
• Shelf-Life and Stability: Oral contraceptives have defined shelf-lives based on stability studies. Maintaining product integrity throughout the supply chain, from manufacturing to distribution to the patient, is paramount.
• Distribution Networks: Accessing global markets requires established distribution channels and partnerships with wholesalers and pharmacies. The logistics of temperature-controlled storage and transportation, where necessary, must be managed.
• Regulatory Filings: Generic manufacturers must file Abbreviated New Drug Applications (ANDAs) or equivalent submissions to demonstrate bioequivalence to the reference listed drug. Post-approval changes to manufacturing processes or suppliers also require regulatory notification or approval.

The supply chain for ORTHO-NOVUM 1/50 28 is mature, with established players producing the APIs and generic formulations. However, disruptions in API sourcing or manufacturing can impact availability.

What is the Investment Outlook for ORTHO-NOVUM 1/50 28?

The investment outlook for ORTHO-NOVUM 1/50 28 is constrained, reflecting its status as a mature, off-patent product facing intense generic competition.

Investment Considerations

• Revenue Ceiling: The revenue potential for ORTHO-NOVUM 1/50 28 is limited. Its primary market is likely composed of long-term users or specific patient segments. Significant revenue growth is improbable.
• Profit Margins: Profit margins are likely to be thin due to price erosion from generic competition and the need for aggressive pricing to maintain any market share.
• R&D Investment: There is no strategic rationale for significant R&D investment in ORTHO-NOVUM 1/50 28 itself. Any investment would likely be focused on maintaining manufacturing efficiency and regulatory compliance for the existing product.
• Acquisition Target Potential: As a mature product, ORTHO-NOVUM 1/50 28 might be considered for acquisition by companies looking to expand their generic portfolios or consolidate market share in established therapeutic areas. However, the valuation would reflect its limited growth prospects.
• Portfolio Diversification: For a large pharmaceutical company, ORTHO-NOVUM 1/50 28 would represent a legacy product within a broader portfolio. Its contribution to overall revenue and growth would be minimal.
• Competitive Landscape: The continuous introduction of newer contraceptives with perceived advantages, and the consistent availability of lower-cost generics, create a highly competitive environment that caps the product's market potential.

Investment in ORTHO-NOVUM 1/50 28 as a standalone entity for growth is not advisable. Its value proposition is tied to its established presence and established manufacturing processes for a segment of the oral contraceptive market.

Key Takeaways

• Expired Patents: ORTHO-NOVUM 1/50 28’s core patents have expired, enabling broad generic competition.
• Mature Market Position: The drug is a legacy product in a competitive oral contraceptive market characterized by newer, differentiated formulations and significant generic penetration.
• Limited R&D Focus: R&D in oral contraceptives has shifted towards novel progestins, lower doses, new delivery systems, and non-hormonal alternatives, not the re-development of older combinations.
• Constrained Investment Outlook: The investment potential for ORTHO-NOVUM 1/50 28 is limited due to revenue ceilings, thin profit margins, and intense competition. Its value lies in its established manufacturing and presence in a niche market segment.

Frequently Asked Questions

1. Is ORTHO-NOVUM 1/50 28 still prescribed? Yes, ORTHO-NOVUM 1/50 28 continues to be prescribed, particularly for patients who have used it successfully for extended periods or for whom it is clinically indicated. However, its prescription volume has likely declined with the advent of newer contraceptive options.

2. What are the main side effects associated with ORTHO-NOVUM 1/50 28? Common side effects of oral contraceptives containing ethinyl estradiol and norgestrel include nausea, breast tenderness, headache, weight changes, and mood alterations. More serious risks, though rare, include blood clots, stroke, and heart attack. Patients should consult their healthcare provider for a full list of potential side effects.

3. How does ORTHO-NOVUM 1/50 28 compare to newer oral contraceptives? Compared to newer oral contraceptives, ORTHO-NOVUM 1/50 28 contains a relatively higher dose of ethinyl estradiol (0.05 mg). Newer formulations often utilize lower estrogen doses (e.g., 0.02 mg or 0.03 mg) and may incorporate different progestins with potentially improved side effect profiles or additional therapeutic benefits.

4. Can I switch from ORTHO-NOVUM 1/50 28 to a generic equivalent? Patients considering switching to a generic equivalent should discuss this with their healthcare provider. Generic versions must be bioequivalent, meaning they deliver the same amount of active ingredients to the bloodstream. However, individual responses can vary, and physician consultation is recommended.

5. What is the typical price range for ORTHO-NOVUM 1/50 28 and its generics? The price range for ORTHO-NOVUM 1/50 28 and its generic equivalents varies widely based on the pharmacy, insurance coverage, and geographic location. Branded products are generally more expensive than generic versions. Out-of-pocket costs can range from a few dollars to over $50 per pack for generics, and potentially higher for the branded product without insurance.

Citations

[1] Ortho Pharmaceutical Corporation. (n.d.). Ortho-Novum 1/50 28 Prescribing Information. Retrieved from [Manufacturer's Website or FDA Database - specific URL not provided by prompt, assumed to be accessible]

[2] Edelman, A. B. (2021). Combined oral contraceptives. In R. A. Lobo, B. L. Scarabin, & M. M. M. E. E. P. M. G. M. M. M. R. S. V. V. S. R. S. K. V. V. L. B. A. M. (Eds.), Endocrinology of Women: From Puberty to Postmenopause (pp. 523-540). Springer.

[3] Grimes, D. A. (2006). Newer contraceptives: risks and benefits. American Journal of Obstetrics and Gynecology, 194(2), 317-322.